1. Introduction {#sec0005}
===============

Myocardium is continuously exposed to metabolic stress. In health, it responds to episodes of increased physical activity and β-adrenergic stimulation, while in disease it suffers from lack of oxygen and inefficient metabolic waste removal (reviewed by [@bib0130; @bib0165]). Much research has been focused on development of methods to protect the myocardium from metabolic stress. In these regards, there are studies showing that estrogen protects cardiomyocytes against stress (reviewed by [@bib0120]). As postmenopausal decline in estrogens level is associated with increase in incidence of cardiovascular diseases in women, it was considered that estrogens replacement would decrease incidence and improve prognosis of these diseases in women. However, clinical studies failed to fulfill such expectations ([@bib0125; @bib0210; @bib0005]) and, as a result, the potential use of estrogen replacement to address a problem of cardiovascular diseases in postmenopausal women is much reduced ([@bib0065]). On the other hand, there are some recent reports suggesting that decline of androgen in women is also a factor in development of cardiovascular diseases after menopause ([@bib0115; @bib0160]).

A recent clinical study demonstrated that a testosterone supplementation improves functional capacity in elderly female patients suffering from heart failure ([@bib0070]). In addition, more recent study reported that testosterone is cardioprotective in ovariectomised rats ([@bib0110]). These findings prompted us to consider possible mechanisms of testosterone-induced cardioprotection in females. In males, cardioprotection afforded by testosterone has been associated with the regulation of expression of some signaling factors including heat shock protein 70 ([@bib0205]), α- and β-adrenergic receptors ([@bib0200]). However, these effects are mediated via androgenic receptors and it is unclear what mechanism would testosterone activate in female hearts when the level of these receptors is so low ([@bib0205; @bib0200]).

To address this question, we have used a pure population of female embryonic rat heart H9c2 cells, which are established model to study mechanisms of cardioprotection ([@bib0035; @bib0095; @bib0100]). Using this experimental model, we have found that testosterone protects female H9c2 cells by activating estrogen receptors and up-regulating a mitochondrial sulfonylurea receptor 2B intraexonics splice variant (IES SUR2B).

2. Methods {#sec0010}
==========

2.1. H9c2 cells {#sec0015}
---------------

Experiments were performed on pure population of rat embryonic heart-derived female H9c2 cells as provided by the manufacturer (ECACC, Salisbury, UK). They were cultured in a tissue flask containing DMEM medium and were supplemented with 2 mM glutamine and 10% FCS in 96-well plate. The cells were split on two occasions before the addition of the hormones using 2 μl trypsin and were then stored at 37 °C at 5% CO~2~. Then either testosterone (100 nM), hydroxyflutamide (1 μM), tamoxifene (1 μM), cycloheximide (1 μg/ml), 17β-estradiol (E2; 100 nM), finasteride (100 ng/ml) and anastrozole (100 μM) alone or combined were added into the culture media and methanol was added to the control group (concentrations used were based on affinities of these ligands). The cultures were then left for a 24 h incubation period before experimentation. All experiments were run in parallel.

2.2. Sex determination in H9c2 cells {#sec0020}
------------------------------------

Genomic DNA was extracted from the rat hearts or H9c2 cells using Wizard SV Genomic DNA Purification System (Promega, Madison, WI) according to the manufacturer\'s recommendations. Genomic DNA was used as a template for real rime RT-PCR. The specific primers for rat sex determining region Y (Sry) were designed using Beacon Designer 3.0 software (Bio-Rad), sense, 5′-CACACTATCATATACGGACAG-3′, antisense, 5′-TGGACAGTA AGTA GGTTAGC-3′, 211bp of PCR product. Real time RT-PCR was performed as described for androgen receptors.

2.3. Cell survival assay {#sec0025}
------------------------

The survival of H9c2 cells were assayed using Multitox-Fluor Multiplex Cytotoxicity Assay (Promega). After 24 h of pretreatment with different testosterone and/or different drugs, 2,4-dinitrophenol (DNP) was added to each well at the final concentration of 10 mM. To measure cell survival 6 h later, the peptide substrate (GF-AFC) that can be cleaved only by live cells was added to the each well. Following 30 min-long incubation at 37 °C, plates were measured using 1420 Multibabel Counter (Victor) plate reader, with excitation at 370 nm and emissions of 480 nm. The percentage of live cells was calculated based on the intensity of fluorescence according to the manufacturer instructions ([@bib0095; @bib0100]).

2.4. Real time RT-PCR {#sec0030}
---------------------

Real time RT-PCR was performed as described in our previous papers ([@bib0040; @bib0170; @bib0180]). Briefly, total RNA was extracted from H9c2 cells or rat hearts using TRIZOL reagent (Invitrogen, Carlsbad, CA) and purified (Qiagen, Crawley, UK) according manufacturer\'s instruction. The samples were diluted 50 times by adding 98 μl of Multi-Q dH~2~O to 2 μl of RNA. The required weight of RNA in each was 4 μg and the total volume in each sample required was 21 μl. The reverse transcription reaction was carried out with ImProm-II™ Reverse Transcriptase System (Promega, Southhampton, UK). A final volume of 20 μl of reverse transcription reaction mix was required. The reaction mixture was prepared by the following process. The ImProm-II™ Reaction buffer (8 μl); 0.5 mM each of dATP, dCTP, dGTP, and dTTP was added along with 2 μl ImProm-II™ reverse transcriptase. RNasin^®^ Ribonuclease inhibitor (1 μl) was added to prevent the RNA being degraded. 3 mM MgCl~2~ was also added to allow the reverse transcriptase enzyme to function more efficiently. Finally 2 μl of deoxynucleoside triphosphate (dNTP) was added to allow the RNA to elongate as well as 0.5 μg of oligo (dT). The reaction mix was added to 1 μg of RNA and was incubated at 42 °C for 1 h. Afterwards it was heated to 70 °C for 15 min to allow the primers to bind and was then annealed for 5 min at 25 °C. Each component of the reverse transcription reaction was multiplied by 13 to give enough template for duplicate samples for each gene for use in PCR. The resulting cDNA was used as template for real-time PCR. The specific primers for rat androgen receptor, sarcolemma K~ATP~ channel subunits and associated proteins (SUR1, SUR2A, SUR2B, Kir6.1, Kir6.2, adenylate kinase (AK), creatine kinase (CK), glyceraldehyde 3-phospho dehydrogenase (GAPDH) and muscle form of lactate dehydrogenase (M-LDH) and IES SUR2A and IES SUR2B were designed using Beacon Designer 3.0 software (Bio-Rad) and are depicted in [Table 1](#tbl0005){ref-type="table"}. GAPDH was also used as a control gene and a loading control. The primers ability to produce no signal in negative controls by dimer formation was used to test specificity. The real time RT-PCR reaction used a SYBR Green I system as previously described ([@bib0095; @bib0100]). The reaction mixture consisted of -- 12.5 μl iQ™ SYBR^®^ Green Supermix (2×), 10 μl of ddH~2~O, 7.5 nM of each primer, and 2 μl of cDNA. The final reaction mixture volume in each well was 25 μl. Each sample was done in duplicate. For the androgen receptor and Sry, the PCR thermal cycling conditions started with a denaturation at 95 °C for 3 min. This was followed by a 38 cycle three step process consisting of 10 s of denaturing at 95 °C, 15 s of annealing at 56 °C and 50 s of extension at 72 °C. For the sarcolemmal K~ATP~ channel subunits and associated proteins, the PCR thermal cycling conditions started with a denaturation at 95 °C for 30 s. This was followed by a 38 cycle three step process consisting of 10 s of denaturing at 95 °C, 15 s of annealing at 56 °C, and 40 s of extension at 72 °C. For the IES SUR2A and IES SUR2B, the thermal cycling conditions were as follows: an initial denaturation at 95 °C for 3 min, followed by 40 cycles of 10 s of denaturing at 95 °C, 15 s of annealing at 56 °C, and 30 s of extension at 72 °C. Following each cycle, data was collected and displayed graphically using an iCycler iQ™ Real-time Detection System Software (iCycler iQ™ Real-time Detection System Software, version 3.0A, BioRad, Hercules, CA). Real-time PCR was performed in the same wells of a 96-well plate using the iCycler iQ™ Multicolor Real-Time Detection System (Bio-Rad, Hercules, CA). The PCR efficiency was examined by analysis of standard curves and melting curves were used to check the PCR specificity. The corresponding no-RT mRNA sample was always included as a negative control. The relative expression ratio(R) of a gene encoding sarcolemmal or mitochondrial K~ATP~ channel forming protein is calculated using equation *R* = (*E*~K~)^ΔCP^~k~^(C−T)^/(*E*~R~)^ΔCP^~R~^(C−T)^ where *E*~K~ is the real time PCR efficiency of a gene of interest transcript, *E*~R~ is the real time PCR efficiency of a reference gene (GAPDH), ΔCP~K~ is the crossing point deviation of control (C)--testosterone treated (T) of gene of interest gene transcript while ΔCP~R~ is the crossing point deviation of control (C)--testosterone treated (T) of a reference gene transcript ([@bib0170]).

2.5. Statistical analysis {#sec0035}
-------------------------

Data are presented as mean ± S.E.M, with *n* representing the number of independent experiments that were run in parallel. Mean values were compared by the ANOVA followed by Student\'s *t*-test, Mann--Whitney rank sum test or by Chi-square test where appropriate using SigmaStat program (Jandel Scientific, Chicago, Illinois). *P* \< 0.05 was considered statistically significant.

3. Results {#sec0040}
==========

3.1. Testosterone protects female H9c2 cells against severe metabolic stress {#sec0045}
----------------------------------------------------------------------------

To make sure that experiments would be performed on a pure female population of H9c2 cells, we have tested whether Sry was present in genomic DNA of these cells. We have found that no Sry-specific product was obtained by real time RT-PCR in H9c2 cells ([Fig. 1](#fig0005){ref-type="fig"}A), while it was found in genomic DNA from male adult hearts as well as in mixes of different proportions of male and female genomic DNAs ([Fig. 1](#fig0005){ref-type="fig"}A). Similarly as in H9c2 cells, no specific Sry product was found in genomic DNA from adult female hearts ([Fig. 1](#fig0005){ref-type="fig"}A).

DNP is known metabolic inhibitor that was used with success to induce severe metabolic stress in H9c2 cells. When applied, this compound inhibits oxidative phosphorylation and ATP production leading to cell death. Under control conditions, 49.5 ± 1.4% (*n* = 32) of cells died after exposure to DNP (10 mM) ([Fig. 1](#fig0005){ref-type="fig"}B). When the same type of stress was imposed on cells pre-treated with testosterone (100 nM), survival in the presence of DNP (10 mM) was significantly increased (39.4 ± 1.4% cells died, *n* = 34, *P* \< 0.001; [Fig. 1](#fig0005){ref-type="fig"}B).

3.2. Protein synthesis de novo is required for testosterone-mediated cytoprotection, but the cytoprotection is not mediated via androgen receptors in female H9c2 cells {#sec0050}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cycloheximide is an inhibitor of protein biosynthesis by interfering with the translocation step in protein synthesis thus blocking translational elongation. Pretreatment with cyclohexamide (1 μg/ml) did not have an effect on cell survival on its own (50.9 ± 1.5% of cells died in the presence of 10 mM DNP, *n* = 13, *P* = 0.36 when compared to the control of 48.3 ± 1.0%, *n* = 13; [Fig. 2](#fig0010){ref-type="fig"}A), but it abolished testosterone-induced cytoprotection (10 mM DNP induced death of 49.7 ± 1.7% cells when pre-treated with both 100 nM testosterone and 1 μg/ml cyclohexamide, *n* = 13, *P* = 0.01 when compared to testosterone group of 39.9 ± 1.3%; [Fig. 2](#fig0010){ref-type="fig"}A). Such findings implied genomic effect of testosterone that is normally mediated by androgen receptors. To determine whether androgen receptors mediate observed cytoprotection afforded by testosterone, we have used hydroxyflutamide, a well established antagonist of these receptors. Hydroxyflutamide (1 μM) on its own did not affect cell survival in the presence of DNP (10 mM; 50.8 ± 3.6% of cells died after challenge with 10 mM DNP, *n* = 7, *P* = 0.70 when compared to the control of 49.6 ± 1.1%, *n* = 7; [Fig. 2](#fig0010){ref-type="fig"}B). Hydroxyflutamide (1 μM) did not block cytoprotection afforded by 100 nM testosterone (10 mM DNP induced death of 43.8 ± 3.7% cells when pre-treated with both 100 nM testosterone and 1 μM hydroxyflutamide, *n* = 6, *P* = 0.72 when compared to testosterone group of 40.7 ± 3.7%, *n* = 6; [Fig. 2](#fig0010){ref-type="fig"}B). In addition, real time RT-PCR revealed that the level of expression of androgen receptors in H9c2 cells was very low ([Fig. 2](#fig0010){ref-type="fig"}B).

3.3. Conversion into compound(s) activating estrogen receptors mediates cytoprotection afforded by testosterone {#sec0055}
---------------------------------------------------------------------------------------------------------------

One unlikely possibility was that testosterone exhibited its effect via activation of estrogen receptors. Tamoxifene is a known partial agonist of estrogen receptors that act as an antagonist in a presence of full receptor agonist. On its own, pre-treatment with tamoxifene (1 μM) has no effect on 10 mM DNP-induced cell death (49.8 ± 1.6% cells died after challenge with 10 mM DNP, *n* = 9, *P* = 0.70 when compared to the control of 48.6 ± 1.6%, *n* = 9; [Fig. 3](#fig0015){ref-type="fig"}A), but it abolished cytoprotection afforded by 100 nM testosterone (10 mM DNP induced death of 52.5 ± 2.6% cells when pre-treated with both 100 nM testosterone and 1 μM tamoxifene, *n* = 8, *P* = 0.006 when compared to testosterone group of 39.3 ± 1.4%; *n* = 9, [Fig. 3](#fig0015){ref-type="fig"}A).

Testosterone is not an agonist of estrogen receptors and it was therefore unlikely that testosterone-induced cytoprotection was mediated via direct interaction with estrogen receptors. However, it is known that testosterone can be converted into metabolites that activate estrogen receptors by 5α-reductase and aromatase. To explore a possibility that cytoprotection by testosterone is due to its conversion, we have tested the effect of inhibitors of 5α-reductase and α-aromatase. Finasteride and anastrozole are well established inhibitors of 5α-reductase and aromatase respectively. On its own, finasteride (100 ng/ml) did not significantly affect cellular susceptibility to DNP (10 mM; DNP induced death of 54.8 ± 1.9% cells pretreated with finasteride, *n* = 6, *P* = 0.26 when compared to the control of 49.5 ± 1.7%, *n* = 6, [Fig. 3](#fig0015){ref-type="fig"}B), but its presence abolished cytoprotection by testosterone (100 nM), and even exacerbated the effect of DNP (10 mM) as 80.2 ± 5.4% of H9c2 cells died when pretreated with finasteride (100 ng/ml) and testosterone (100 nM) combined ([Fig. 3](#fig0015){ref-type="fig"}B). On its own anastrozole (100 μM), exacerbated the effect of DNP (10 mM; 73.7 ± 7.1% cells pretreated with anastrozole died in response to DNP), but the difference was not significantly different from controls of 55.7 ± 4.9% (*P* = 0.07 when compared with control, *n* = 5 for each, [Fig. 3](#fig0015){ref-type="fig"}C). Testosterone (100 nM) did not increase survival of cells challenged with DNP (10 mM) when incubated in combination with anastrozole (100 μM; 66.7 ± 3.4% cells died, *n* = 5 for each, *P* = 0.40 when compared with anastrozole alone, [Fig. 3](#fig0015){ref-type="fig"}C). As these results supported idea that conversion of testosterone and the activation of estrogen receptors protects female H9c2 cells against severe metabolic stress, we have tested whether known agonist of these receptors 17β-estradiol (E2) would have similar cytoprotective effect. Pretreatment of H9c2 cells for 24 h with E2 (100 nM) significantly improve cellular survival in response to DNP (10 mM) as 53.3 ± 5.4% cells died under control conditions and only 30.7 ± 2.7% cells died when pretreated by E2 (100 nM, *P* = 0.003, *n* = 6 for each, [Fig. 3](#fig0015){ref-type="fig"}D).

3.4. Testosterone does not affect expression of sarcolemmal K~ATP~ channel subunits and accessory proteins {#sec0060}
----------------------------------------------------------------------------------------------------------

Experiments with pharmacological tools up to that particular point suggested that testosterone is cytoprotective by activating estrogen receptors which seemed to be due to conversion of testosterone to a compound that activates these receptors. It has been previously shown that 17β-estradiol (E2), a main estrogen, confers cytoprotection in H9c2 cells by up-regulating SUR2A, an ABC protein serving as a regulatory subunit of sarcolemmal ATP-sensitive K^+^ (K~ATP~) channels ([@bib0080]). An increase in SUR2A increases levels of sarcolemmal K~ATP~ channels ([@bib0040]) that confers cytoprotection by virtue of their channel and non-channel properties ([@bib0045]). In addition, sarcolemmal K~ATP~ channels have been suggested to be end-effectors of cardioprotective signaling pathway activated by ischemic preconditioning ([@bib0015; @bib0175]). It has been established that sarcolemmal K~ATP~ channels are composed of Kir6.2 and SUR2A subunits (reviewed by [@bib0080]). However, more recent studies suggested sarcolemmal K~ATP~ channel protein complex can contain more subunits/accessory proteins including Kir6.1, Kir6.2, SUR1, SUR2A, SUR2B, adenylate kinase (AK), creatine kinase (CK), muscle form of lactate dehydrogenase (M-LDH) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ([@bib0020; @bib0025; @bib0030; @bib0090]). Real time RT-PCR did not reveal any statistically significant difference in mRNA levels of GAPDH as a control gene as well as eight additional K~ATP~ channel-forming subunits between untreated and 100 nM testosterone-treated female H9c2 cells ([Fig. 4](#fig0020){ref-type="fig"}). At the same time, pretreatment with E2 (100 nM) did result in increased SUR2A mRNA levels ([Fig. 4](#fig0020){ref-type="fig"}; threshold cycles under control conditions and when pretreated with E2 were 27.4 ± 0.2 and 26.7 ± 0.2 respectively, *n* = 9 for each, *P* = 0.017), while E2 did not have effect on GAPDH as a control gene (threshold cycles under control conditions and when pretreated with E2 were 14.7 ± 0.2 and 14.6 ± 0.1 respectively, *n* = 9 for each, *P* = 0.55).

3.5. Testosterone regulates expression of mitochondrial sulfonylurea receptor 2B (IES SUR2B) splice variants and this seems to mediate cytoprotection {#sec0065}
-----------------------------------------------------------------------------------------------------------------------------------------------------

In many studies, mitochondrial K~ATP~ (mK~ATP~) channels have been suggested to play a central role in cardioprotective signaling (reviewed by [@bib0055]). Mitochondrial K~ATP~ channels have been described for the first time in 1991 ([@bib0075]), but they are not yet fully understood. One of the most studied and disputed issue about mK~ATP~ channels is their structure. From 1997 until these days different proteins and subunits have been suggested to form mK~ATP~ channels ([@bib0185; @bib0155; @bib0105; @bib0230]). Most recently, it has been shown that SUR2A and SUR2B generated by non-conventional intraexonic splicing (IES SUR2A and B) physically associate with Kir6.2 to form mK~ATP~ channels ([@bib0225]). Both of these variants regulate Kir6.2 activity and IES SUR2B has been shown to be involved in cardioprotection ([@bib0225]). Therefore, we have assessed whether testosterone regulates the expression of IES SUR2A and IES SUR2B. For IES SUR2A under control conditions the threshold cycles value was 28.5 ± 0.6 (*n* = 6) and that was not significantly different from this value in cells pretreated with 100 nM testosterone (threshold cycles: 28.6 ± 0.7, *n* = 6, *P* = 0.98). For IES SUR2B threshold cycles value was 33.7 ± 0.3 (*n* = 6) and this was significantly higher than those value for cells pretreated with 100 nM testosterone (threshold cycles: 31.8 ± 0.3, *n* = 6, *P* \< 0.001). GAPDH as a control gene was not affected (threshold cycles under control conditions and when pretreated with testosterone were 16.5 ± 0.3 and 16.2 ± 0.2 respectively, *n* = 6 for each, *P* = 0.70). Although IES SUR2B has been already associated with cardioprotection ([@bib0225]), we looked for more evidence about connection between testosterone-induced cardioprotection and IES SUR2B up-regulation. Therefore, we have examined whether tamoxifene, a partial agonist of estrogen receptors that abolished testosterone-mediated effect on female H9c2 cells, would affect in any way testosterone-induced up-regulation of IES SUR2B. On its own, tamoxifene (1 μM) did not significantly alter levels of IES SUR2A and IES SUR2B mRNA levels in comparison to control one (IES SUR2A: threshold cycles under control conditions and when pretreated with tamoxifene were 28.9 ± 0.2 and 28.8 ± 0.3 respectively, *n* = 6 for each, *P* = 0.91, [Fig. 5](#fig0025){ref-type="fig"}; IES SUR2B: threshold cycles under control conditions and when pretreated with tamoxifene were 33.3 ± 0.2 and 33.4 ± 0.3 respectively, *n* = 6 for each, *P* = 0.97, *n* = 6 for each, [Fig. 5](#fig0025){ref-type="fig"}) neither it affected the expression of GAPDH (threshold cycles under control conditions and when pretreated with testosterone were 16.0 ± 0.1 and 16.1 ± 0.1 respectively, *n* = 6 for each, *P* = 0.88). However, testosterone (100 nM) was unable to up-regulate IES SUR2A and IES SUR2B in the presence of tamoxifene (1 μM) (threshold cycles in this case was 28.3 ± 0.3, *n* = 6 for IES SUR2A and 32.9 ± 0.3 for IES SUR2B; [Fig. 5](#fig0025){ref-type="fig"}) and also did not affect expression of control GAPDH (threshold cycles under control conditions and when pretreated with testosterone were 16.0 ± 0.1 and 16.1 ± 0.1 respectively, *n* = 6 for each, *P* = 0.88). We have then examined whether E2 would affect the expression of IES SUR2A and IES SUR2B. Pretreatment of female H9c2 cells with E2 (100 nM) did not affect level of IES SUR2A (threshold cycles when pretreated with E2 was 28.7 ± 0.2 respectively, *n* = 6, *P* = 0.64 when compared to the control value; [Fig. 5](#fig0025){ref-type="fig"}). In contrast, E2 (100 nM) did up-regulate IES SUR2B (threshold cycles when pretreated with E2 was 32.2 ± 0.2 respectively, *n* = 6, *P* = 0.003 when compared to the control value; [Fig. 5](#fig0025){ref-type="fig"}). The level of a control gene, GAPDH, was not affected (threshold cycles under control conditions and when pretreated with testosterone were 16.7 ± 0.2 and 16.8 ± 0.1 respectively, *n* = 6 for each, *P* = 0.75).

4. Discussion {#sec0070}
=============

The effect of testosterone on myocardial resistance to ischemia has been studied and recent reports suggest that chronic treatment with this hormone is cardioprotective in males ([@bib0205; @bib0200]). In females, testosterone effect on the heart has not been extensively studied, but there are clinical and experimental in vivo reports supporting a possible cardioprotective role of testosterone in females ([@bib0115; @bib0160]). The results obtained in the present study would support such notion, as we have found that testosterone protected female H9c2 cells against severe metabolic stress induced by DNP.

Testosterone is a steroid hormone that exhibits its physiological effects mostly by regulating the expression of certain genes (reviewed by [@bib0140]). In the present study, we have shown that cyclohexamide, an inhibitor of protein synthesis, abolished testosterone-mediated cytoprotection suggesting that genomic effect is responsible for the observed testosterone action. As one would expect, testosterone mediate its effects mainly by activating androgen receptors ([@bib0195]). However, our experiments by real time RT-PCR has demonstrated that there is a low level of expression of androgen receptors in female H9c2 cells, which would make cytoprotection via androgen receptors rather unlikely. Indeed, antagonist of androgen receptors, hydroxyflutamide ([@bib0010]), did not alter the effect of testosterone whatsoever, effectively excluding a possibility that androgen receptors mediate testosterone-induced cytoprotection in female H9c2 cells.

It has been previously described that the activation of estrogen receptors (ER) in female cells results in increase in cellular resistance to a range of different stresses ([@bib0085; @bib0120]). Testosterone has low affinity and intrinsic activity for ER ([@bib0140]), but we have still tested an unlikely possibility that these receptors could be involved in testosterone-induced cytoprotection. Tamoxifene is a partial agonist that acts as antagonist of ER in the presence of a full agonist ([@bib0050]). This compound did not significantly affect cell survival under DNP on its own, suggesting that full agonistic activity at ER is essential if cytoprotection is to be achieved. On the other hand, tamoxifene blocked the effect of testosterone. This would suggest that the activation of ER mediate testosterone-induced increase in cellular resistance to metabolic stress. This was surprising result when considering that testosterone cannot activate ER ([@bib0140]). In both sexes testosterone acts not only as a ligand for androgen receptors but also as a precursor for other steroids. Importantly testosterone can be converted to 5α-dihydrotestosterone (DHT) by the 5α-reductase enzyme or to estradiol in a number of tissues by the aromatase enzyme ([@bib0060]). To test a possibility that testosterone-induced cytoprotection is mediated by conversion of this hormone to its metabolites, we conducted cell survival experiments with finasteride and anastrozole. We found that both finasteride, a 5α-reductase inhibitor ([@bib0150]), and anastrozole, an aromatase inhibitor ([@bib0150]), abolished the protective effect of testosterone. This strongly suggests that conversion of testosterone is required for observed cytoprotective effect. The identity of the metabolite(s) mediating cardioprotection afforded by testosterone is yet to be determined, but there are many possibilities. Besides obvious one, estradiol, which cardioprotective effect was also confirmed in this study, 3β-diol or 3α-diol are also realistic option as 5α-reductase converts testosterone to DHT which is then subsequently converted to these metabolites. It has been demonstrated that 3β-diol and 3α-diol can bind and activate ER ([@bib0135; @bib0220]). In addition to that, a role of some other metabolite of testosterone cannot be excluded. In the heart, testosterone can be metabolized into androstendione, 5α-androstane, 2α-HT, 6α-HT, 7α-HT, 16α-HT, 6β-HT and 5α-androstane ([@bib0190]). This is a whole array of metabolites and a substantial research is further required to identify all testosterone metabolites occurring in our experimental conditions and link them to the observed effect of cytoprotection. Nevertheless, at the present moment in time, we can suggest that testosterone metabolite(s), and not testosterone directly, mediate cytoprotection in female H9c2 cells.

Cardioprotection by activation of ER is not a surprise, as there are reports showing that different isoforms of ER are important in mediating myocardial protection in females ([@bib0215; @bib0220]). Wang et al. (2006) demonstrated that ERα contributes to acute myocardial protection in females possibly via differential activation of mitogen-activated protein kinase (MAPK). The same group then went on to show in a later study that ERβ also improves myocardial function in female mice hearts after acute ischemia by activation of the phosphoinositide 3 kinase/protein kinase B (PI3K/PKB) signaling system ([@bib0220]). We have previously shown that estrogens up-regulate SUR2A, a regulatory subunit of sarcolemmal K~ATP~ channels, and consequently increase the number of these channels. K~ATP~ channels have been suggested as end-effectors of ischemic preconditioning ([@bib0015]) and acute increase in number of K~ATP~ channels in sarcolemma is a feature of preconditioning ([@bib0175]). An up-regulation of SUR2A alone is sufficient to increase numbers of sarcolemmal K~ATP~ channels, which in turn increases cardiac resistance to stress by virtue of channel and non-channel properties of these channels ([@bib0080; @bib0045]). As SUR2A expression is regulated by estrogens ([@bib0145]; also confirmed in the present study) and testosterone-derived metabolites that activate ER mediate observed cytoprotection, it was logical to test whether testosterone would up-regulate SUR2A. Our experiments showed that it did not. In addition, testosterone also did not affect expression of any other K~ATP~ channel-forming subunit or accessory protein showing that testosterone-mediated cytoprotection is not associated with up-regulation of sarcolemmal K~ATP~ channels. Why SUR2A is not increased following activation of ER is not clear at the moment. It is possible that metabolites other than E2, such as 3β-diol and/or 3α-diol or some others, play a crucial role in mediating such effect or that simultaneous presence of E2 and/or other metabolites competing with E2 to ER modify the signaling outcome of ER activation. Nevertheless, the obtained results strongly suggest that regulation of expression of SUR2A is not a part of signaling pathway mediating testosterone effect on female H9c2 cells.

In addition to sarcolemmal K~ATP~ channels, K~ATP~ channels localized on mitochondrial inner membrane (mK~ATP~ channels) have been also implicated into cardioprotection. In fact, there are a lot reports claiming that these channels play a central role in the cardioprotective signaling pathway(s) (reviewed by [@bib0055]). The composition of these channels is not yet established ([@bib0185; @bib0155; @bib0105; @bib0230]). The most recent suggestion is that mitochondrial K~ATP~ channels are composed of Kir6.2, as a pore-forming subunit, and IES SUR 2A or IES SUR2B ([@bib0225]). It has been demonstrated that IES SUR2B regulate myocardial resistance to metabolic stress ([@bib0225]). Therefore, we have examined a possibility that IES SUR2A and IES SUR2B are regulated by testosterone. The obtained results suggested that IES SUR2A is not regulated by testosterone. In contrast, IES SUR2B was up-regulated by testosterone and this is the first report ever identifying a factor/hormone that regulates IES SUR2B. It has been previously shown that increased level of IES SUR2B generates cardioprotective phenotype ([@bib0225]) and from this prospective it would be logical to conclude that up-regulation of IES SUR2B mediates cardioprotection afforded by testosterone. However, as there are no tools available to inhibit up-regulation of IES SUR2B, we have looked for additional circumstantial evidence. As tamoxifene inhibits cytoprotection afforded by testosterone, it would be expected that this compound would also affect testosterone-induced up-regulation of IES SUR2B, as opposed to the same for IES SUR2A. This is exactly what happened in our experimentation, confirming a notion that testosterone protect embryonic rat heart H9c2 cells against severe metabolic stress by up-regulating IES SUR2B. This is further supported by our finding that E2 also specifically up-regulates IES SUR2B. This is the first time ever that a regulation of IES SUR2B expression was demonstrated to be a part of cytoprotective signaling. It is quite possible that IES SUR2B regulate the number of functional mK~ATP~ channels in a similar manner as SUR2A subunit regulate the number of fully assembled sarcolemmal K~ATP~ channels ([@bib0080]). Consequently, an increase in number of cardioprotective mK~ATP~ channels induced by testosterone would foster a cardioprotective outcome.

In conclusion, this study has shown that testosterone protect female embryonic heart H9c2 cells against severe metabolic stress by its conversion into metabolite(s) that activate estrogen receptors and up-regulate IES SUR2B. The obtained results suggest that testosterone could be used as a therapeutic in females in conditions where increased resistance to metabolic stress would be beneficial, such as ischemic heart disease, heart failure and others. Testosterone is here recognized as the hormone/signaling factor that regulates expression of IES SUR2B, a likely subunit of mK~ATP~ channels.
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![Testosterone protects female H9c2 cells against severe metabolic stress. (A) Representative progress curves for the real-time PCR amplification of Sry genomic DNA from male and female rats mixed in different ratios (as labeled on the figure; from 100% male genomic DNA to 100% female genomic DNA), and from H9c2 cells. (B) A bar graph showing a percentage of control cells, and cells pretreated with testosterone (100 nM) that died after treatment with DNP (10 mM). Each bar represent mean ± SEM (*n* = 32--34). \**P* \< 0.01 when compared to the control.](gr1){#fig0005}

![Genomic effect mediates testosterone-induced cytoprotection without involving androgen receptors in female H9c2 cells. (A) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM) and cycloheximide (1 μg/ml) alone and together. Each bar represent mean ± SEM (*n* = 13 for each). \**P* \< 0.05 when compared to the testosterone group. (B) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM) and hydroxyflutamide (1 μM) alone and together. Each bar represent mean ± SEM (*n* = 6--7). \**P* \< 0.05 when compared to the testosterone group. (B1) Representative progress curves for the real-time PCR amplification of androgen receptor cDNA from male rats and H9c2 cells.](gr2){#fig0010}

![Conversion of testosterone and activation of estrogen receptors is required for testosterone-mediated cytoprotection in female H9c2 cells. (A) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM) and tamoxifene (1 μM) alone and together. Each bar represent mean ± SEM (*n* = 9 for each). \**P* \< 0.05 when compared to the testosterone group. (B) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM) and finasteride (100 ng/ml) alone and together. Each bar represent mean ± SEM (*n* = 6 for each). \**P* \< 0.05 when compared to the testosterone group. (C) A bar graph showing a percentage of control cells, cells pretreated with testosterone (100 nM) and anastrozole (100 μM) alone and together. Each bar represent mean ± SEM (*n* = 5 for each). \**P* \< 0.05 when compared to the testosterone group. (D) A bar graph showing a percentage of control cells, and cells pretreated with 17β-estradiol (E2; 100 nM) that died after treatment with DNP (10 mM). Each bar represent mean ± SEM (*n* = 6 for each). \**P* \< 0.01 when compared to the control.](gr3){#fig0015}

![Testosterone does not regulate the expression of sarcolemmal K~ATP~ channel subunits and accessory proteins in female H9c2 cells. Relative expression ratio (treated/untreated ratio of mRNA calculated as described in Section [2](#sec0010){ref-type="sec"}) of depicted channel subunits and accessory proteins pretreated with either testosterone (100 nM) or E2. Each bar represents mean ± SEM (*n* = 6).](gr4){#fig0020}

![Testosterone regulates the expression of IES SUR2B, but not IES SUR2A. Relative expression ratio (treated/untreated ratio of mRNA calculated as described in Section [2](#sec0010){ref-type="sec"}) of IES SUR2A and IES SUR2B under conditions depicted on graphs. Each bar represents mean ± SEM (*n* = 6). \**P* \< 0.05 when compared to the control.](gr5){#fig0025}

###### 

Rat primers used in real time RT-PCR experiments.

  mRNA                 Sense                        Antisense
  -------------------- ---------------------------- -----------------------------
  SUR 1                5′-GGAAGGACTC                5′-GAGACCATC
  ACCACCATC-3′         AAGGCATAGG-3′                
  SUR 2A               5′-ACTTCAGCGT                5′-AGCAGGTTTGG
  TGGACAGAGAC-3′       ACCAGTATCG-3′                
  SUR 2B               5′-GACGCCA                   5′-TCATCACAATG
  CTGTCACCGAAG-3′      ACCAGGTCAGC-3′               
  Kir 6.1              5′-GTCACACGCTG               5′-GGCACTCCTCAG
  GTCATCTTCAC-3′       TCATCATTCTCC-3′              
  Kir 6.2              5′-TGGCTGACGAG               5′-TGGCGGGGCTG
  ATTCTGTGG-3′         TGCAGAG-3′                   
  GAPDH                5′-ATAGAATTCC                AGCCTCGAGTTA
  ATGACAAAGTGGAC       GGAAATGAG                    
  ATTGTTGCCA-3′        CTTCACAAAGTT-3′              
  Androgen receptors   5′-AGCCACC GCCTCTTCTTC -3′   5′-ACCAGGATACCA CACTTCAG-3
  IES SUR2A            5′-AGTTGGGGTGGG AGGTCAG-3    5′-TGCAGAGAATGA GACACTTG-3
  IES SUR2B            5′-AGTTGGGGTGGG AGGTCAG-3    5′-ACCCGATGAGCTA TGGTTAC -3
